446,764 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC acquired a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 446,764 shares of the company's stock, valued at approximately $5,915,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new position in Takeda Pharmaceutical in the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC raised its holdings in Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical in the fourth quarter valued at approximately $52,000. Cromwell Holdings LLC acquired a new stake in shares of Takeda Pharmaceutical during the fourth quarter worth $61,000. Finally, Venturi Wealth Management LLC raised its position in shares of Takeda Pharmaceutical by 554.7% in the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after acquiring an additional 4,260 shares during the period. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Down 1.4%

Shares of NYSE:TAK traded down $0.20 during trading on Monday, hitting $14.17. 5,381,637 shares of the company were exchanged, compared to its average volume of 1,903,078. The stock has a market cap of $45.07 billion, a price-to-earnings ratio of 35.41, a P/E/G ratio of 0.24 and a beta of 0.26. The firm has a fifty day moving average price of $14.87 and a two-hundred day moving average price of $14.00. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.43. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The company had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. As a group, research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research note on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.